CN102429912B - 一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 - Google Patents
一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 Download PDFInfo
- Publication number
- CN102429912B CN102429912B CN 201110329663 CN201110329663A CN102429912B CN 102429912 B CN102429912 B CN 102429912B CN 201110329663 CN201110329663 CN 201110329663 CN 201110329663 A CN201110329663 A CN 201110329663A CN 102429912 B CN102429912 B CN 102429912B
- Authority
- CN
- China
- Prior art keywords
- prasterone
- pharmaceutical composition
- sodium
- micropowder
- dheas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title claims abstract description 46
- GFJWACFSUSFUOG-ZJTJBYBXSA-M sodium dehydroepiandrosterone sulfate Chemical compound [Na+].C1[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 GFJWACFSUSFUOG-ZJTJBYBXSA-M 0.000 title claims abstract description 21
- 229960002847 prasterone Drugs 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 27
- 238000009826 distribution Methods 0.000 claims abstract description 10
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 6
- 206010071018 Urogenital atrophy Diseases 0.000 claims abstract description 5
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 11
- 229920002261 Corn starch Polymers 0.000 claims description 10
- 239000008120 corn starch Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- -1 liquid Paraffin Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 3
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 39
- 239000000843 powder Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 26
- 238000004090 dissolution Methods 0.000 description 25
- 241000700159 Rattus Species 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000007941 film coated tablet Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000011121 vaginal smear Methods 0.000 description 3
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940089931 gris-peg Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
时间(分) | 普粉片 I | 普粉片II | 微粉片 III | 微粉片 IV |
0 | 0 | 0 | 0 | 0 |
4 | 12.54 | 19.99 | 31.67 | 29.82 |
8 | 22.85 | 37.81 | 57.99 | 55.34 |
12 | 32.78 | 52.79 | 83.57 | 80.46 |
16 | 43.82 | 68.83 | 95.67 | 95.11 |
20 | 52.96 | 75.61 | 98.89 | 97.35 |
24 | 63.72 | 82.37 | 99.35 | 98.89 |
28 | 72.46 | 86.29 | 99.72 | 99.33 |
32 | 78.71 | 88.41 | 99.67 | 99.19 |
36 | 80.37 | 89.69 | 100.0 | 99.83 |
时间(分) | 普粉胶囊1 | 普粉胶囊 2 | 微粉胶囊 3 | 微粉胶囊 4 |
0 | 0 | 0 | 0 | 0 |
4 | 11.35 | 19.11 | 41.68 | 31.32 |
8 | 21.02 | 36.33 | 58.83 | 57.16 |
12 | 31.66 | 51.26 | 86.91 | 81.32 |
16 | 39.98 | 68.03 | 95.83 | 95.23 |
20 | 49.87 | 75.36 | 98.19 | 96.61 |
24 | 62.35 | 81.51 | 99.05 | 98.77 |
28 | 68.67 | 86.27 | 99.28 | 99.01 |
32 | 74.57 | 88.23 | 99.82 | 98.59 |
36 | 74.87 | 89.83 | 99.96 | 99.83 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110329663 CN102429912B (zh) | 2011-10-26 | 2011-10-26 | 一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110329663 CN102429912B (zh) | 2011-10-26 | 2011-10-26 | 一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102429912A CN102429912A (zh) | 2012-05-02 |
CN102429912B true CN102429912B (zh) | 2013-04-24 |
Family
ID=45978499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110329663 Active CN102429912B (zh) | 2011-10-26 | 2011-10-26 | 一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102429912B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104983696A (zh) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | 硫酸普拉睾酮钠分散片及其制备方法 |
CN104983706B (zh) * | 2015-06-04 | 2018-10-30 | 湖北生物医药产业技术研究院有限公司 | 硫酸普拉睾酮钠缓释片及其制备工艺 |
CN104983717A (zh) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | 硫酸普拉睾酮钠缓释胶囊及其制备方法 |
CN104983705B (zh) * | 2015-06-04 | 2018-11-30 | 湖北生物医药产业技术研究院有限公司 | 硫酸普拉睾酮钠缓释片及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19825856A1 (de) * | 1998-06-10 | 1999-12-16 | Labtec Gmbh | Topische Arzneimittelzubereitung |
CN1231217C (zh) * | 2002-12-25 | 2005-12-14 | 庞飞 | 一种治疗更年期综合征的药物 |
CN1931159B (zh) * | 2005-09-16 | 2010-05-12 | 天津药物研究院 | 艾拉莫德微粉化及口服速释制剂 |
CN100490796C (zh) * | 2007-07-06 | 2009-05-27 | 北京化工大学 | 一种亚微米级吉非罗齐药物粉体的制备方法 |
-
2011
- 2011-10-26 CN CN 201110329663 patent/CN102429912B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102429912A (zh) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI235658B (en) | beta-carboline drug products | |
JP5538386B2 (ja) | フェルラ酸とマトリン類化合物を含有する薬物組成物及びその製造方法と用途 | |
CN102429912B (zh) | 一种微粉化普拉睾酮或硫酸普拉睾酮钠制备的药物组合物及其用途 | |
CN103768063B (zh) | 一种盐酸莫西沙星药物组合物及其制备方法 | |
CN104352442B (zh) | 一种米非司酮壳聚糖缓释微球制剂及其制备方法 | |
WO2016029496A1 (zh) | 美索舒利片剂及其制备方法 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
CN105769872B (zh) | 一种快速溶出的枸橼酸莫沙必利组合物 | |
CN107595798A (zh) | 一种琥珀酸普芦卡必利片剂及其制备方法 | |
CN101653580B (zh) | 一种治疗胃病的药物及其制备方法 | |
CN103356495B (zh) | 一种来曲唑片剂及其制备方法 | |
CN112023056B (zh) | 一种氟康唑药物组合物及其制备方法 | |
CN108283628A (zh) | 一种抗癌药物微囊制剂及其制备方法 | |
CN108186590A (zh) | 石杉碱甲缓释口崩片及其制备方法 | |
CN109381431B (zh) | 石杉碱甲缓释微丸及其制备方法 | |
CN103432090B (zh) | 一种环维黄杨星d舌下片及其制备方法和用途 | |
CN103908435B (zh) | 一种氟他胺缓释制剂及其制备方法 | |
CN109394709A (zh) | 一种包含艾瑞昔布的药物组合物 | |
CN114712343B (zh) | 一种携载光甘草定的脾靶向纳米药物的制备方法及应用 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
CN108210448A (zh) | 硝酸芬替康唑栓剂及其应用 | |
CN104116719B (zh) | 一种石杉碱甲调释片组合物及其制备方法 | |
CN104013611A (zh) | 芒果苷元及衍生物在制备抗前列腺增生药物中的应用 | |
Guo et al. | Therapeutic Effect of Triptolide Polymer Mesoscale Nanoparticles on Diabetic Nephropathy Mice | |
CN108685867A (zh) | 一种赛洛多辛薄膜衣片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. Effective date: 20150619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150619 Address after: 100006 Beijing city Dongcheng District south along the zijingong hotel room 509 Beijing Kang Mai Dike Biological Technology Development Co Ltd Patentee after: Pang Fei Patentee after: Mayinglong Pharmaceutical Group Co., Ltd. Address before: 100006 Beijing city Dongcheng District south along the zijingong hotel room 509 Beijing Kang Mai Dike Biological Technology Development Co Ltd Patentee before: Pang Fei |